Drug Trial Radar · NCT07161999
Study of COYA 302 for the Treatment of ALS
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Apr 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Coya TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) in a 1:1:1 ratio for 24 weeks in the double-blind (DB) period. Those who complete this part of the study will be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). Upon completion of the EXT phase of the study, participants will be invited to participate in an open label extension (OLE). The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302Drug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R)Time frame: Baseline to Week 24
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
California Pacific Medical Center
San Francisco, California
Nova Southeastern University
Davie, Florida
University of Florida Clinical and Translational Research Center
Gainesville, Florida
University Of Miami
Miami, Florida
University of South Florida
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern
Chicago, Illinois
Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University
St Louis, Missouri
Neurology Associates, P.C. Somnos Clinical Research
Lincoln, Nebraska
Columbia University Medical Center ALS Center
New York, New York
Thomas Jefferson University-Weinberg ALS Center
Philadelphia, Pennsylvania
Temple Neurology
Philadelphia, Pennsylvania
Austin Neuromuscular Center; National Neuromuscular Research Institute, PLLC
Austin, Texas
Texas Neurology, PA
Dallas, Texas
Houston Methodist Stanley H. Appel Department of Neurology
Houston, Texas
The University of Texas Health Science Center
San Antonio, Texas
University of British Columbia
Vancouver, British Columbia, Canada
London Health Sciences Center
London, Ontario, Canada
University of Toronto/Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
Hopital Neurologique de Montreal
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.